1. Pink Sheet

Prescription Pathways' Friendly Divorce

 
• By Michael McCaughan

The Prescription Pathways joint venture will dissolve at the end of 2008, with CVS Caremark and Universal/MemberHealth divvying up the assets of one of the larger Part D plans. As divorces go, this seems amicable. But what about the children? Or in this case, the elderly and disabled Medicare beneficiaries who may be surprised to learn that they have been transferred to a new plan sponsor.

The Prescription Pathways joint venture will dissolve at the end of 2008, with CVS Caremark and Universal/MemberHealth divvying up the assets of one of the larger Part D plans. As divorces go, this seems amicable. But what about the children?

Prescription Pathways was one of the more innovative business arrangements created to launch Part D, a joint venture of CVS...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.